Gain Therapeutics, Inc.

GANX Nasdaq SEC CIK 1819411
Follow Gain Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.2M +40.2% vs same quarter last year
EPS, diluted −$0.07 +53.3% vs same quarter last year
Operating cash flow −$3M +38.1% vs same quarter last year
Operating income −$3.2M +33.1% vs same quarter last year
Net income by quarter
−$3.8M
−$4.5M
−$5.8M
−$5.3M
−$4.5M
−$5.6M
−$4.7M
−$3.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$20.2M
FY24-−$20.4M
FY23$55.2K−$22.3M
FY22$132.6K−$17.6M
FY21$133.9K−$13.9M
FY20$28.9K−$3.6M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23−40328.3%−40354.3%
FY22−13402.5%−13262%
FY21−10323.6%−10371.7%
FY20−12047.5%−12387.7%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$18.9M
FY23−$18.9M
FY22−$14.8M
FY21−$12.5M
FY20−$3.3M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Gain Therapeutics
  • Healthcare median
−60000%−40000%−20000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGain TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23−40354.3%−58%
FY22−13262%−80.4%
FY21−10371.7%−71.8%
FY20−12387.7%−62.2%
FY19-−46.2%